Atriscal (Dexibuprofen) is used in situations involving certain distressing symptoms, including those associated with inflammatory or irritative states and conditions where functional stability becomes affected. The medication is considered relevant when supportive symptom management is appropriate across several therapeutic domains.

Atriscal is used in areas where short-term symptom management is appropriate. It is considered relevant for easing the pain and inflammation associated with conditions characterized by periods of heightened symptoms, such as Osteoarthritis, and may be part of symptomatic management for Rheumatoid Arthritis. It may assist with easing acute localized discomfort, including headache, toothache, and post-procedural pain. Furthermore, the medication is considered relevant for easing fever and episodic visceral pain like the cramping associated with Primary Dysmenorrhea.

This offers symptomatic relief that contributes to easing the overall symptom load during difficult episodes, assisting with maintaining functional stability.

Quick Fact: Relief for Pain and Inflammation
Symptom Axes	Physical discomfort, inflammatory states, heightened physiological activity
Typical Context	Acute localized pain, chronic joint stiffness, episodic cramping, systemic fever
Patient Benefit	Contributes to improved comfort and supports relief of the overall symptom load

Who Can and Cannot Use Atriscal?

Eligibility for Atriscal (Dexibuprofen) is strictly defined by regulatory documents, which establish clear restrictions based on pre-existing conditions, age, and physiological status.

Contraindicated Populations (Must Not Use)

Atriscal is absolutely contraindicated for specific populations due to the risk of severe complications, as documented in official labeling. These include individuals with severe heart failure (NYHA Class IV), severe renal dysfunction (GFR < 30 ml/min), or severely impaired hepatic function. Use is prohibited in patients with active or history of recurrent peptic ulcer/haemorrhage, or a history of GI bleeding related to previous NSAID therapy. Patients with known hypersensitivity to any NSAID, or those who develop asthma or bronchospasm following NSAID use, must not use this medicine. Furthermore, Atriscal is contraindicated during the third trimester of pregnancy.

Age and Conditional Eligibility

Use is generally not recommended for children younger than 12 years due to insufficient data on established safety and efficacy. Older adults should commence treatment at the lowest possible dose and require close monitoring. Patients with mild to moderate hepatic or renal impairment may use the medicine, but only with a reduced starting dose and necessary monitoring of organ function. During the first and second trimesters of pregnancy, the medicine should be used only if clearly necessary, at the lowest dose for the shortest time.

Official Interaction Profile of Atriscal

Atriscal (Dexibuprofen) is subject to formally documented interactions that are classified based on the mechanism of interference or the severity of the clinical outcome, as outlined in official regulatory labeling.

Classification	Interacting Product Category	Documented Interaction Outcome
Prohibited Combination	Other NSAIDs and Analgesic-Dose Acetylsalicylic Acid	Increases the documented risk of gastrointestinal ulceration and haemorrhage.
Increased Exposure Risk	Lithium, Methotrexate (high dose)	Increases plasma concentrations of co-administered medicine by documented reduction of renal clearance, raising toxicity potential.
Pharmacodynamic Risk	Anticoagulants, Corticosteroids, SSRIs	Increases the documented risk of serious bleeding or gastrointestinal adverse events.
Reduced Efficacy Risk	Diuretics and Antihypertensives	Diminishes the intended blood pressure-lowering and fluid-regulating effects.

Interaction-Specific Constraints

Interaction with low-dose Acetylsalicylic Acid (Aspirin) for cardio-protection requires specific administration timing to minimize documented interference with its antiplatelet effect. Atriscal must be taken at least 30 minutes after or at least 8 hours before the immediate-release aspirin dose.

Interaction risks are formally documented as being more significant in elderly patients. Furthermore, co-administration with Antihypertensives or Diuretics carries an increased risk of acute renal failure in patients with pre-existing renal or cardiac impairment.

Primary Mechanism: Reversible Inhibition of Cyclooxygenase (COX) Enzymes

Atriscal (Dexibuprofen) exerts its action by functioning as a reversible, non-selective inhibitor of the Cyclooxygenase (COX) enzyme system, specifically COX-1 and COX-2. This mechanism prevents the critical conversion of Arachidonic Acid into prostaglandins—the local chemical messengers that drive pain signaling, inflammation, and fever. The drug provides the active S(+)-enantiomer, which is the component responsible for inhibiting the activity of these key enzymes.

---

Mechanistic Cascade: Dual Central and Peripheral Pathway Modulation

The reduction in prostaglandin synthesis affects key pathways both locally and systemically. Peripherally, lower concentrations of Prostaglandin E2 ( PGE2) at sites of injury reduce the sensitization of nociceptors, which raises the stimulus threshold of the pain-sensing nerve fibers. Centrally, PGE2 inhibition in the hypothalamus helps reset the body’s internal temperature threshold. This dual modulation reflects the comprehensive physiological alterations achieved through pathway suppression.

---

Temporal Constraint and Scope of Action

The physiological effects driven by Atriscal are intrinsically time-limited because the drug binds non-covalently to the COX enzymes. This reversible interaction means that the enzyme activity is restored once the concentration of Dexibuprofen in the bloodstream and tissues decreases. The mechanism provides temporary suppression of signaling within heightened physiological pathways through reversible enzyme inhibition.

Atriscal is administered via the oral route using film-coated tablets which contain the active substance, Dexibuprofen. The tablet strengths are available in 200 mg, 300 mg, and 400 mg dosages. The 200 mg and 400 mg tablets feature a score line to facilitate breaking the tablet for ease of swallowing.

The standard daily regimen for adults typically ranges from 600 mg to 900 mg, with the total amount divided into up to three single doses. A single dose must not exceed 400 mg. For the temporary management of acute symptoms, the daily dose may be transiently increased to a maximum of 1200 mg. The general usage principle requires administering the lowest effective dose for the shortest duration necessary for symptomatic control.

Administration is permissible either with or without a meal. However, to minimize the potential for gastrointestinal irritation, the tablets are preferably taken with food. It is noted that taking the medicine simultaneously with or immediately following a meal may result in a delay in the onset of its effects.

Specific instructions for use apply to certain populations. For older adults, treatment is initiated at the lower end of the dosage range. Similarly, patients identified with mild to moderate renal or hepatic impairment are required to begin therapy at reduced doses and be monitored closely. Use is generally not recommended for children and adolescents under 18 years of age.

Research Evidence / Overview of Studies for Atriscal

Evidence for Symptomatic Relief in Osteoarthritis

Research has explored Atriscal in painful osteoarthritis, primarily of the knee or hip. The evidence relies on short-term randomized controlled trials (RCTs) where researchers examined outcomes related to physical discomfort and daily functioning, using tools like the WOMAC Osteoarthritis Index. Comparative evidence indicated patterns in symptom measurements similar to those reported for other studied agents. The core trials had limited follow-up durations, typically around 14 days, meaning the long-term durability of the symptomatic relief is not individually characterized beyond the general NSAID class.

Evidence for Acute Pain Relief in Primary Dysmenorrhea

Atriscal's use in the acute visceral pain associated with primary dysmenorrhea (menstrual cramping) has been explored through randomized, double-blind, crossover clinical trials. These studies monitored episodic changes and examined patient-reported pain relief scores and the duration of the analgesic effect. Findings described patterns tracked against specific doses of the racemic ibuprofen compound. Research focuses on the acute management of pain, and broader comparative evidence against different classes of pain relievers is lacking.

Evidence in Specific Patient Populations

Most research explored the use of Atriscal in cohorts of generally healthy adults experiencing the target conditions.

• Older Adults: Included in the osteoarthritis research, but data for patients with significant pre-existing health conditions may be insufficient.
• Children and Adolescents: Research for these specific uses has mainly focused on adult populations, and the results apply only to the populations studied in the adult trials.

Research Gaps and Areas of Uncertainty

A primary limitation is that many comparison trials were designed to demonstrate non-inferiority, meaning the goal was to show that measured outcomes were not worse than the established comparator, rather than showing a distinct therapeutic advantage. Further, while short-term patterns were observed consistently across studies, there is limited information for long-term outcomes and for how symptoms change over sustained use in the context of chronic conditions. The research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index

Common questions about Atriscal (FAQ)

---

Q: Is Atriscal a narcotic or controlled substance?

A: Atriscal (Dexibuprofen) is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official regulatory classifications confirm that the medication is not designated as a narcotic or a controlled substance.

Q: How quickly does Atriscal typically start working?

A: Clinical studies focusing on acute pain relief report that the effects of Atriscal are often detectable within the first one to three hours after a dose is administered. This time frame reflects when a significant number of study participants first reported achieving pain relief.

Q: What should someone do if they miss a dose of Atriscal?

A: Official patient information generally advises taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose and continue with the regular schedule. Regulatory guidance advises against doubling the dose to make up for a missed one.

Q: Can Atriscal affect a person's ability to drive or operate machinery?

A: Regulatory documents state that a person's ability to drive or operate complex machinery might be affected if they experience certain side effects. Official guidance suggests avoiding these activities if effects like dizziness or drowsiness are noticed after taking the medication.

Q: Are there any known withdrawal symptoms associated with stopping Atriscal?

A: Atriscal is a non-opioid medication. Its official product labeling does not typically list specific physical withdrawal symptoms associated with the cessation of its use, nor is it associated with dependence.

Q: How long after taking Atriscal should I wait before consuming alcohol?

A: Regulatory sources state that patients should avoid or limit alcohol consumption while taking Atriscal. This is due to the potential for alcohol to increase the risk of serious gastrointestinal adverse events, such as bleeding in the stomach or intestines.

Q: Does Atriscal cause weight gain or weight loss?

A: Significant changes in body weight are not typically listed as common adverse events. However, official documents note that NSAIDs like Atriscal may cause fluid retention and edema (swelling), which is documented as potentially resulting in fluctuations in weight.

Q: Is there a risk of developing a tolerance to Atriscal over time?

A: Atriscal is classified as a non-opioid pain reliever. Official regulatory documents do not describe the development of tolerance for the medication.

Q: Are there any specific supplements or vitamins that should be avoided while taking Atriscal?

A: Regulatory warnings require caution when Atriscal is combined with any non-medicinal substance, including supplements or vitamins, that could increase the risk of bleeding or affect liver function. Users are advised to check for potential interactions with any product that might affect blood clotting.

Q: Does Atriscal interact with common over-the-counter pain relievers?

A: Atriscal is strictly contraindicated (prohibited) for use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). For non-NSAID relievers like acetaminophen (paracetamol), caution is still advised by regulatory bodies, particularly concerning overlapping risks of toxicity with long-term combined use.

Q: What is the difference between Atriscal and similar medications used for the same condition?

A: Atriscal is distinct because it contains only Dexibuprofen, which is the single pharmacologically active component, or S(+)-enantiomer, of the conventional ibuprofen compound. This is known as a chiral switch, focusing on the delivery of the therapeutically effective substance.

Q: What is the typical expected duration of treatment with Atriscal?

A: Official regulatory guidance requires that Atriscal be used for the shortest duration necessary to control symptoms. For acute pain or fever, the use is typically short-term. The determination of the exact duration is made by a healthcare provider.

Q: What is the safety profile of Atriscal during pregnancy or while breastfeeding?

A: Atriscal is strictly contraindicated during the third trimester of pregnancy due to specific risks to the fetus. Regarding breastfeeding, official review indicates that the active ingredient passes into breast milk in very low concentrations, but official guidance indicates that use during this period should be determined based on medical necessity.

Q: Is there an increased risk of specific mental health changes while on Atriscal?

A: Adverse events reported in official documents include nervous system disorders like dizziness and headache. Less commonly, psychiatric reactions such as anxiety, nervousness, or mood disturbances have also been documented alongside these effects.

Q: What type of medical professional typically prescribes Atriscal?

A: Atriscal is primarily authorized as a prescription-only medicine (POM) in many regions. As such, it is typically prescribed by a physician or another authorized healthcare professional.

Q: Are there different brand names for the medication that is in Atriscal?

A: Yes, the active ingredient, Dexibuprofen, is authorized and marketed internationally under various different brand names that differ depending on the country and the pharmaceutical manufacturer.

Q: Do specific genetic factors influence how a person responds to Atriscal?

A: Regulatory science acknowledges that genetic variations in metabolic enzymes, such as CYP2C9, may influence how the body processes NSAIDs. This can potentially result in differences in how individual patients respond to Dexibuprofen.

Q: Is there a generic version of Atriscal available?

A: Yes, following the expiry of patents for the active substance Dexibuprofen in many international regions, generic versions of the medicine have been authorized and are available.

Q: How effective is Atriscal compared to placebo in clinical trials?

A: Clinical study reports confirm that single doses of Atriscal provide a significantly higher degree of pain relief compared to an inactive substance (placebo). This effectiveness pattern has been demonstrated in trials for acute pain conditions.

Q: Are there dietary restrictions required when taking Atriscal?

A: Official guidance permits taking Atriscal with or without food. No specific dietary restrictions are universally mandated, though taking the dose with food is preferred to help minimize potential gastrointestinal irritation.

Q: What happens if Atriscal is taken at a higher dose than prescribed?

A: Taking a dose higher than prescribed can lead to symptoms such as nausea, vomiting, abdominal pain, or dizziness. Severe overdose can cause serious effects like central nervous system depression or acute renal failure. Official documents emphasize that immediate medical attention is required in cases of suspected overdose.

Q: Does Atriscal require any specific laboratory tests before starting treatment?

A: Official labeling mandates monitoring of renal (kidney) and hepatic (liver) function during long-term therapy. However, regulatory documents do not explicitly require specific laboratory tests before initiating treatment unless the patient has a pre-existing medical condition.

Q: Does Atriscal need to be tapered off, or can it be stopped abruptly?

A: As an NSAID, Atriscal does not typically require a gradual reduction (tapering) and can generally be stopped abruptly. Regulatory guidance suggests consulting a physician regarding cessation, especially for chronic conditions.

Q: Can Atriscal affect sleep patterns?

A: Official documents list side effects that could potentially impact sleep. These include general nervous system effects like drowsiness and, less commonly, psychiatric effects such as insomnia or nervousness.

Q: What is the most important piece of safety information about Atriscal to remember?

A: The most emphasized safety information in regulatory documents highlights the risk of serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding or ulceration). This risk is documented as potentially increasing with higher doses or longer duration of use.

Q: Is Atriscal considered safe for people with diabetes?

A: Regulatory documents include diabetes mellitus as a cardiovascular risk factor. Regulatory guidance advises careful consideration before initiating long-term treatment, especially at high doses, for patients with diabetes.

Q: Do official documents mention any potential for dependence on Atriscal?

A: No, official documents and regulatory classifications do not mention any potential for physical or psychological dependence on Atriscal, as it is a non-opioid NSAID.

Q: Are there any specific warning signs of an adverse reaction to Atriscal?

A: Official information advises patients to immediately seek medical help if they experience key warning signs of a serious reaction. These signs include chest pain, sudden difficulty breathing, passing blood in stool, severe abdominal pain, swelling of the face or throat, or a severe skin rash.

Q: Does Atriscal interact with herbal products like St. John's Wort?

A: While specific herbal products are often not listed in official drug interactions, regulatory caution is generally required for any herbal supplement that carries an additive risk of bleeding or affects the central nervous system.

How to Store and Dispose of Atriscal

Official regulatory guidelines define specific requirements for storing and disposing of Atriscal to maintain its stability and ensure environmental safety.

Storage and Disposal Requirement	Official Regulatory Statement
Storage Temperature	Store below 25 C (or as specified on the label). Do not freeze or refrigerate.
Environmental Protection	Keep the medicine in its original packaging. Protect from light and moisture.
Child Safety	Keep Atriscal out of the sight and reach of children.
Disposal Instructions	Dispose of unused or expired product according to local regulations. Do not dispose of via household waste or wastewater.

The official storage profile mandates adherence to temperature limits and environmental protection constraints to preserve the product's integrity. For disposal, regulatory standards require the return of unused medicine to authorized collection sites, preventing pharmaceutical waste from entering the water system.